Elicio Therapeutics (ELTX) Enterprise Value (2020 - 2026)

Elicio Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$14.9 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 21.47% year-over-year to -$14.9 million; the trailing twelve-month figure through Mar 2026 stood at -$14.9 million (up 21.47% YoY), and the FY2025 full-year result was -$18.6 million, up 1.24% from the prior year.
• Enterprise Value for Q1 2026 stood at -$14.9 million, up from -$18.6 million in the prior quarter.
• The five-year high for Enterprise Value was -$598000.0 in Q2 2022, with the low at -$73.0 million in Q1 2022.
• Historically, Enterprise Value has averaged -$17.7 million across 5 years, with a median of -$16.5 million in 2023.
• Annual changes were most pronounced in 2022 — Enterprise Value surged 99.49% — and 2023, when it plunged 3525.75%.
• Elicio Therapeutics' Enterprise Value stood at -$7.8 million in 2022, then slumped by 74.63% to -$13.6 million in 2023, then tumbled by 38.04% to -$18.8 million in 2024, then grew by 1.24% to -$18.6 million in 2025, then increased by 19.47% to -$14.9 million in 2026.
• The last three Enterprise Value figures came in at -$14.9 million (Q1 2026), -$18.6 million (Q4 2025), and -$20.6 million (Q3 2025), per Business Quant data.